Joseph Zakrzewski's Trading History
| ANTXAN2 Therapeutics, Inc. | Aug 14, 2026 | Director | Uninformative Sell | ― | $659.29K | |
| CYTCyteir Therapeutics | Dec 08, 2022 | ― | Informative Buy | 27.56K | $1.13M | |
| SGMOQSangamo Therapeutics | Mar 01, 2022 | Director | Uninformative Buy | ― | $7.04K | |
| AMRNAmarin | Dec 16, 2021 | Director | Informative Buy | 38.90K | $2.38M | |
| XLRNAcceleron Pharma | Nov 22, 2021 | ― | Uninformative Sell | ― | $0.00 | |
| PODDInsulet | May 18, 2017 | Director | Uninformative Buy | ― | $4.17M | |
| LPDXLipoScience | Nov 24, 2014 | ― | Uninformative Sell | 133.20K | ― |
You May Also Like
Joseph Zakrzewski insider profile FAQ
What is the percentage of profitable transactions made by Joseph Zakrzewski?
The percentage of profitable transactions made by Joseph Zakrzewski is 53%.
What is the average return per transaction made by Joseph Zakrzewski?
The average return per transaction made by Joseph Zakrzewski is 18.50%.
What stocks does Joseph Zakrzewski hold?
Joseph Zakrzewski holds: ANTX, PODD, SGMOQ, CYT, AMRN, LPDX, XLRN stocks.
What was Joseph Zakrzewski's most profitable transaction?
Joseph Zakrzewski’s most profitable transaction was an Informative Buy of XLRN stock on June 17, 2019. The return on the trade was 155.10%.
What is Joseph Zakrzewski's role in AN2 Therapeutics, Inc.?
Joseph Zakrzewski's role in AN2 Therapeutics, Inc. is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.
TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.